Vor Biopharma Inc at TD Cowen Healthcare Conference Transcript
Okay, well, good morning, everybody, and thank you so much for joining us for the 46th annual TD Cowen Healthcare Conference. I'm Yaron Werber from the Biotech team, and it's really a great pleasure to have with us today, Vor Therapeutics, and Jean-Paul Kress, the Chief Executive Officer.
Vor -- telitacicept is a BAFF/APRIL inhibitor with really promising data in both Phase 3 in gMG and Sjögren's. The gMG data is gonna come midyear and first patient in for the Phase 3 global Sjögren's study is gonna be by the end of the first half of this year. We've written extensively about both opportunities. gMG looks really promising based on the data, and we're equally to frankly even more excited about Sjögren's, which is frankly a big white space.
So, Jean-Paul, thanks so much for joining us. We appreciate it. We'll do a presentation and then Q&A.
Thank you, Yaron, and good morning, everyone. Very
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
